|Bid||1.35 x 3100|
|Ask||1.50 x 900|
|Day's Range||1.41 - 1.45|
|52 Week Range||1.15 - 7.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep 10, 2018 - Sep 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has allowed the Company’s IND application for its ADXS-HOT drug candidate for non-small cell lung cancer (NSCLC). Advaxis anticipates that because of this timely allowance, the first patient in the Phase 1/2 trial for this NSCLC drug candidate will be dosed by the end of 2018.
LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on ADXS sign up now at www.wallstequities.com/registration. On Wednesday, July 25, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories.
Advaxis (ADXS), in collaboration with Merck & Co. (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda in patients with previously treated metastatic, castration-resistant prostate cancer. In the trial, 13 patients were evaluated on monotherapy and 37 patients were evaluated on combination therapy. The safety profile was found to be consistent with prior clinical studies that used Lm Technology.
Advaxis (ADXS) is conducting a Phase 1 Part 2 open-label multicenter study for evaluating the safety and efficacy of axalimogene filolisbac in combination with durvalumab. Durvalumab is MedImmune’s investigational anti-PD-L1 checkpoint inhibitor for patients with metastatic squamous or non-squamous carcinoma of the cervix and metastatic HPV-related squamous cell carcinoma of the head and neck. On March 9, the study was placed on clinical hold by the FDA after its review of a safety report showed a grade-five serious adverse event occurring in February.
In Q2 2018, Advaxis (ADXS) generated revenues of $1.75 million compared to $3.43 million in Q1 2017. The decrease was due to a change in the estimated performance period for upfront fees received by Advaxis from Amgen (AMGN) for the collaboration agreement they signed in August 2016. For fiscal 2018 and 2019, the company is expected to generate revenues of $7.59 million and $7.68 million, respectively.
Advaxis (ADXS) has a license from the University of Pennsylvania for exclusive access to the proprietary formulation of attenuated Lm Technology. Across multiple clinical trials and in various tumor types, more than 530 patients have been dosed with Advaxis’s Lm (listeria monocytogenes) Technology. The company believes that its Lm Technology immunotherapies can complement and address unmet needs in the current oncology treatment landscape.
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want access to our free research report on Advaxis, Inc. (NASDAQ: ADXS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADXS as the Company's latest news hit the wire. On July 11, 2018, the Company announced that the US Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its Phase-1/2 study of axalimogene filolisbac (AXAL). The drug is used in combination with durvalumab for the treatment of patients with advanced, recurrent, or refractory cervical cancer and HPV-associated head and neck cancer.
Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential. HENDERSON, NV / ACCESSWIRE ...
Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22. On July 12, Advaxis stock closed at $1.22 and hit its 52-week low of $1.15. Advaxis hit its 52-week high of $7.45 on September 11, 2017. Today, the FDA lifted its clinical hold on Advaxis’s IND (Investigational New Drug) application for the initiation of its Phase 1/2 trial of a combination therapy of axalimogene filolisbac and AstraZeneca’s (AZN) Imfinzi (duravalumab).
Shares of the late-stage immuno-oncology company Advaxis, Inc. (NASDAQ: ADXS) are adding about one-fifth of their value in the wake of a positive regulatory announcement. The FDA lifted the clinical hold it previously placed on the company's investigational new drug application for its axalimogene filolisbac in combination with durvalumab to treat patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer, according to Advaxis. The FDA imposed a clinical hold March 9 following a safety report of a patient death that occurred Feb. 27 after dosing.
Shares of the biotech company Advaxis Inc. (ADXS) surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The trial is testing a combination of Advaxis' axalimogene filolisbac, a listeria-based immunotherapy, and Astrazeneca's durvalumab (AZN) for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug (IND) application for its Phase 1/2 study of axalimogene filolisbac (AXAL) in combination with durvalumab for the treatment of patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer.
Advaxis’ regulatory action in Europe is based on European Medicines Agency (EMA) feedback following its initial review indicating the application will likely need additional data to support a conditional approval. As previously communicated, Advaxis is actively seeking a partner to support the late-stage cervical cancer program.
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Knowles ...
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has commenced a Phase 1 trial with the dosing of the first patient with ADXS-NEO, an investigational personalized immunotherapy approach targeting personal neoantigens found by sequencing a patient’s own cancer cells. ADXS-NEO is being evaluated in an open-label, dose-escalation, multicenter Phase 1 clinical trial in the United States. The study is open to patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.
On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 27 cents. The biotechnology company posted revenue of $1.7 million in the period. The company's shares closed at $1.71. ...
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a new prioritization of its product portfolio, as well as financial results and business highlights for the three months ended April 30, 2018. The product portfolio review was conducted under the leadership of recently appointed President and CEO Ken Berlin, along with the full Advaxis executive team including recently named Chief Medical Officer Andres Gutierrez, M.D., Ph.D. The process reflects a commitment to allocate capital to programs that meet three criteria: (i) commercially attractive applications for the company’s Lm technology platform, (ii) the opportunity for the Lm platform to meaningfully impact cancer care, and (iii) a rapid and cost-effective route to generate clinical and immunological response data to demonstrate proof of concept.
Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM).
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial Officer, effective June 6, 2018. Ms. Henderson joins Advaxis from Cedar Cliff, LLC, where she served as a financial and business consultant to high-growth entrepreneurial companies. Previously she was Chief Financial Officer at Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) (IOVA), an immuno-oncology company where she was responsible for all financial, SEC reporting, legal, governance, human resources and IT-related functions, and raised $100 million in equity capital.
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 study, conducted in conjunction with Merck (known as MSD outside the United States and Canada) evaluating ADXS-PSA, Advaxis’s Listeria monocytogenes (Lm)-based immunotherapy, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take place on Thursday, June 7, 2018. Advaxis’ senior management will host a conference call to review its financial results and provide a business update. The conference call and live audio webcast will begin at 11:00 a.m. Eastern time on Thursday, June 7, 2018.
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of their Lm vector that presents tumor neoantigens, and is being evaluated in the ADXS-NEO program. ADXS-NEO is derived from the Company’s proprietary Lm Technology and is being developed in partnership with Amgen. These preclinical findings were discussed in poster presentations at the recent American Association for Cancer Research (AACR) Annual Meeting.